Telix share price hits record high on strong quarter and guidance upgrade

This market darling has continued to deliver stunning top line growth.

| More on:
Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is rising again on Thursday morning.

In early trade, the radiopharmaceuticals company's shares have hit a record high of $20.76.

Why is the Telix share price at a record high?

Investors have been bidding the company's shares higher this morning after it released an update on its performance during the second quarter.

According to the release, for the three months ended 30 June, Telix achieved total revenue of approximately US$124 million (A$189 million) This represents an increase of 55% on the prior corresponding quarter and an 8% increase on the previous quarter.

Management advised that this revenue was primarily generated from sales of Telix's prostate cancer imaging product Illuccix in the United States.

Revenue generated from sales of Illuccix in the United States was approximately US$121 million during the three months.

Guidance upgraded

In light of this strong performance, the company has upgraded its revenue guidance for FY 2024.

It now expects revenue to be in the range of US$490 million to US$510 million (A$745 million to A$776 million at current exchange rates). This represents an increase of approximately 48% to 54% on FY 2023's revenue.

Telix was previously guiding to revenue of US$445 million to US$465 million for FY 2024, which means it has lifted its guidance by a sizeable 9.9% at the mid-point. This helps explain why the Telix share price is outperforming today.

This revenue guidance is based on approved products in jurisdictions with a marketing authorisation. Telix has also reaffirmed its guidance for research and development expenditure, which remains at an expected 40% to 50% increase compared with 2023. This will be funded by earnings.

The company's managing director and CEO, Dr Christian Behrenbruch, was rightfully pleased with the quarter. He said:

We have continued to deliver excellent quarterly growth in both revenue and dose volume sales of Illuccix. We have leveraged our unrivalled scheduling flexibility and clinical differentiation, to increase our market share and minimise the impact of new entrants.

Further information, such as profitability, was not released with this update. However, investors won't have to wait long to see if Telix's strong profit growth continued during the quarter.

The company revealed that it plans to release its half year results for the six months ended 30 June on 22 August.

Following today's gain, the Telix share price is now 70% over the past 12 months.

Motley Fool contributor James Mickleboro has positions in Telix Pharmaceuticals. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »